Current Clinical Trials

ALL CANCER TYPES

EAY131: (MATCH) Molecular Analysis for Therapy Choice

Biospecimen Bank: A Biospecimen Bank and Study to Understand Solid Tumor and Hematological Malignancies and Benign Hematology Conditions

Breast Cancer Clinical Trials:

A011106 (ALTERNATE)
Alternate approaches for clinical stage II or III Estrogen Receptor positive breast cancer Neo Adjuvant Treatment (ALTERNATE) in postmenopausal women: A phase III study

A011401: Randomized Phase III Trial Evaluating The Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer

A011202: A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy

NRG-BR003: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node

BCCR: Breast Cancer Collaborative Registry (Non-treatment study)

Gynecological Cancer:

GOG-3015: A Phase III, Multicenter, Randomized, Study of Atezolizumab Versus Placebo Administered in Combination with Paclitaxel, Carboplatin, and Bevacizumab to Patients With Newly Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Hematological Malignancies:

Connect MDS/AML: A Registry for Newly Diagnosed MDS and AML Patients

Lung Cancer Clinical Trials:

A151216 (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial

A081105 (ALCHEMIST)
Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLS)

E4512 (ALCHEMIST)
A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib Versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

EA5142: (ALCHEMIST) Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers

S1400: (LUNG-MAP) A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer

CALGB-30610: Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer Also Receiving Cisplatin or Carboplatin and Etoposide

Website for all clinical trials: www.clinicaltrials.gov

If you require assistance navigating this website, or want more information about our clinical trials, please contact research manager Corilynn Hughes, R.N., B.S.N., O.C.N., at 410-871-6400.